Skip to main content
. Author manuscript; available in PMC: 2018 Jun 1.
Published in final edited form as: J Clin Virol. 2017 Apr 7;91:73–78. doi: 10.1016/j.jcv.2017.04.003

Table 1. HIV-positive final results tested at Zuckerberg San Francisco General Hospital (ZSFG), January -November 2015.

Total (January – Nov, 2015) RT-IF1 (Jan – Aug, 2015) AR-MS-VL2 (Sep – Nov, 2015)
All Testers (N) Previous HIV+ Testers (N) HIV- /Unknown Testers (N) New HIV Infection Prevalence3 (95%CI) Previous HIV+ Testers (N) HIV- /Unknown Testers (N) New HIV Infection Prevalence3 (95%CI)
Total tests done 21,985 197 16,260 77 5,430
HIV+ Cases Identified 321 197 36 0.22% (0.16-0.30) 77 11 0.20% (0.11-0.36)
 Outpatient 15 4 3 0.11% (0.04-0.32) 5 3 0.30% (0.10-0.88)
 OB 6 3 3 0.16% (0.05-0.47) 0 0 0% (0-0)
 Jail 12 4 5 0.28% (0.12-0.66) 1 2 0.30% (0.08-1.08)
 Inpatient 49 36 7 0.51% (0.25-1.05) 6 0 0% (0-0)
 ED 34 25 6 0.45% (0.21-0.98) 2 1 0.23% (0.04-1.31)
 Drop In 69 39 12 0.17% (0.10-0.30) 13 5 0.23% (0.10-0.54)
 HIV clinic 163 86 0 0% (0-0) 77 0 0% (0-0)
1

Uni-Gold HIV Rapid Test (RT) for screening followed by immunofluorescence (IF) confirmation

2

ARCHITECT® HIV Ag/AB Combo (AR) for screening, followed by Multispot HIV-1/HIV-2 Rapid Test (MS) confirmation, and Abbott RealTime HIV-1 assay (VL) as needed for resolution of discrepant results

3

Prevalence is measured among those with HIV-negative or unknown status at the time of testing